(NASDAQ: MRSN) Mersana Therapeutics's forecast annual revenue growth rate of 2.01% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.57%.
Mersana Therapeutics's revenue in 2023 is $40,842,000.On average, 4 Wall Street analysts forecast MRSN's revenue for 2023 to be $5,761,413,407, with the lowest MRSN revenue forecast at $3,153,222,281, and the highest MRSN revenue forecast at $10,370,061,804. On average, 3 Wall Street analysts forecast MRSN's revenue for 2024 to be $6,499,375,945, with the lowest MRSN revenue forecast at $4,823,284,560, and the highest MRSN revenue forecast at $8,440,747,980.
In 2025, MRSN is forecast to generate $4,594,178,543 in revenue, with the lowest revenue forecast at $4,220,373,990 and the highest revenue forecast at $4,967,983,097.